Kutane Non-Hodgkin-Lymphome

  • G. Burg
  • S. Dommann
  • R. Pötter
  • O. Schlappack
  • R. Dummer

Zusammenfassung

Inzidenz: 1–2/100000 pro Jahr. Dabei handelt es sich in 65% der Fälle um kutane T-Zellymphome (CTCL) und in 25% um kutane B-Zellymphome (CBCL); die restlichen 10% verteilen sich auf nicht sicher zuzuordnende oder seltene Entitäten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bamberg M (1987) Spezielle Strahlentherapie der malignen Tumoren: Mycosis fungoides. In: Scherer E (Hrsg): Strahlentherapie. Radiologische Onkologie. Springer Verlag, Berlin Heidelberg New York Tokyo, p 387Google Scholar
  2. Braathen LR, McFadden N (1989) Successful treatment of mycosis fungoides with the combination of etretinate and human recombinant interferon alfa-2 a. J Dermatol Treatment 1: 29 - 32CrossRefGoogle Scholar
  3. Bunn PA Jr, Ihde DC, Foon KA (1987) Recombinant Interferon alfa-2 a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer [Suppl] 1: 9 - 13PubMedCrossRefGoogle Scholar
  4. Burg G, Braun-Falco 0 (1983) in cooperation with: Kerl H, Leder LD, SchmoeckeL C, Wolff HH, Leider M: Cutaneous lymphomas, pseudolymphomas and related disorders. A textatlas covering clinical, histological, cytochemical, immunological and finestructural features. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  5. Burg G (Hrsg) (1987) Recommendations for staging and therapy of cutaneous lymphomas. A European Concept. EORTC Cutaneous Lymphoma Project Group, MünchenGoogle Scholar
  6. Burg G, Kerl H, Thiers B (eds) (1994) Cutaneous lymphomas. Dermatologic Clinics. Saunders, PhiladelphiaGoogle Scholar
  7. Dummer R et al. (1993) Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: Results of a phase I/II study. J Am Acad Dermatol 29: 963 - 970PubMedCrossRefGoogle Scholar
  8. Dummer R et al. (1993) Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Arch Dermatol 129: 433 - 436PubMedCrossRefGoogle Scholar
  9. Heald P, et al. (1992) Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporal photochemotherapy. J Am Acad Dermatol 27: 427 - 433PubMedCrossRefGoogle Scholar
  10. Holloway XB, Flowers FP, Ramos-Caro FA (1992) Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 27: 367 - 378PubMedCrossRefGoogle Scholar
  11. Hoppe RT, Fuks Z, Bagshaw MA (1977) The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Biol Phys 2/9 + 10: 843 - 851CrossRefGoogle Scholar
  12. Joly Petal. (1991) Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients. J Clin Oncol 9: 1994 - 2001Google Scholar
  13. Jones GJ et al. (1992) Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). J Am Acad Dermatol 26: 960 - 967PubMedCrossRefGoogle Scholar
  14. Jörg B et al. (1993) Therapeutic approaches in cutaneous lymphoma. Dermatologic Clinics. Saunders, PhiladelphiaGoogle Scholar
  15. Kaye FJ et al. (1989) A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321: 1784 - 1790PubMedCrossRefGoogle Scholar
  16. Kerl H, Cerroni L, Burg G (1991) The morphologic spectrum of T-cell lymphomas of the skin: A proposal for a new classification. Semin Diagn Pathol 8: 55-61.Google Scholar
  17. Knobler RM et al. (1991) Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa 2b and retinoids. J Am Acad Dermatol 24: 247 - 252PubMedCrossRefGoogle Scholar
  18. Micialy B et al. (1990) The radiation therapy of early stage cutaneous T-cell lymphoma. Int J Radiat Biol Phys 18: 1333 - 1339CrossRefGoogle Scholar
  19. Saven A et al. (1992) 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80:587-592Google Scholar
  20. Springer A et al. (1993) Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous lymphoma treated with interferon alpha-2a. J Am Acad Dermatol 29: 42 - 46PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • G. Burg
  • S. Dommann
  • R. Pötter
  • O. Schlappack
  • R. Dummer

There are no affiliations available

Personalised recommendations